Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial
Posted innews Oncology Urology

Metastasis-Directed Radiotherapy Without Systemic Therapy in Oligometastatic Clear-Cell Renal-Cell Carcinoma: Promising Efficacy and Safety from a Phase 2 Trial

A phase 2 trial demonstrates that carefully selected patients with oligometastatic clear-cell renal-cell carcinoma can achieve prolonged systemic therapy-free survival and favorable progression-free survival using metastasis-directed radiotherapy alone, with limited toxicity.
Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy
Posted inClinical Updates Oncology Specialties Urology

Advancing Treatment in Oligometastatic Castration-Resistant Prostate Cancer: The GROUQ-PCS 9 Trial on SBRT Plus Standard Systemic Therapy

The GROUQ-PCS 9 trial demonstrates that adding stereotactic body radiotherapy to standard androgen deprivation therapy and enzalutamide significantly prolongs radiographic progression-free survival in oligometastatic castration-resistant prostate cancer with manageable toxicity.
Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223
Posted inOncology Urology

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223

The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metastases, with manageable toxicity and importance of bone-protecting agents.